Operational Costs Compared: SG&A Analysis of ADMA Biologics, Inc. and Mesoblast Limited

A Decade of SG&A Trends: ADMA Biologics vs. Mesoblast Limited

In the ever-evolving biotech industry, operational costs are a critical factor in determining a company's financial health. Over the past decade, ADMA Biologics, Inc. and Mesoblast Limited have shown distinct trends in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, ADMA Biologics saw a staggering increase of over 1,100% in SG&A expenses, peaking at approximately $59 million in 2023. In contrast, Mesoblast Limited's SG&A expenses fluctuated, with a notable peak in 2015, followed by a gradual decline to around $53 million in 2023. This divergence highlights the strategic differences in managing operational costs between the two companies. While ADMA Biologics has consistently ramped up its spending, Mesoblast appears to be optimizing its expenses. Understanding these trends provides valuable insights into each company's operational strategies and market positioning.